Foghorn Therapeutics Inc.
FHTX
$5.41
-$0.12-2.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -75.40M | -80.44M | -86.62M | -91.22M | -86.45M |
| Total Depreciation and Amortization | 3.17M | 3.11M | 3.12M | 3.21M | 3.34M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.09M | 14.59M | 15.36M | 16.97M | 19.12M |
| Change in Net Operating Assets | -30.36M | -32.30M | -32.27M | -32.39M | -45.65M |
| Cash from Operations | -90.49M | -95.03M | -100.41M | -103.43M | -109.63M |
| Capital Expenditure | -838.00K | -833.00K | -906.00K | -464.00K | -237.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -1.00K | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.05M | -26.77M | -29.00M | -14.35M | 85.17M |
| Cash from Investing | 24.21M | -27.60M | -29.90M | -14.81M | 84.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.84M | 104.99M | 106.01M | 106.20M | 106.14M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -390.00K | -585.00K | -585.00K | -585.00K | -195.00K |
| Cash from Financing | 1.45M | 104.40M | 105.43M | 105.61M | 105.95M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -64.83M | -18.23M | -24.88M | -12.63M | 81.24M |